Clinical Trials

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06103864 2026-03-31

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

625 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07213804 2026-03-20

FRAmework-01

Phase 3 Recruiting

1,080 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT03631199 2026-02-25

CANOPY-1

Phase 3 Terminated

673 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05374512 2026-01-27

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

644 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT04158362 2025-09-22

AMBRE

180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04879368 2025-07-17

INTEGRATEIIb

450 enrolled

Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT03430843 2024-10-26

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

512 enrolled 27 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT02915744 2023-04-14

ATTAIN

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT02264990 2021-02-26

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

595 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02106546 2020-11-17

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

970 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02322281 2019-08-14

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Phase 3 Terminated

149 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

NCT00876395 2018-12-19

BOLERO-1

719 enrolled 25 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02929576 2018-10-22

ENDEAR

Phase 3 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT01006252 2018-07-17

SUMMIT-1

Phase 3 Terminated

336 enrolled 22 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT00561119 2017-05-01

Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer

326 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT01166542 2014-11-05

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers